RenovoRx, Inc.
- Jurisdiction
United States - ISIN
US75989R1077 (RNXT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Read full profile
Stock price
Fundamentals
- Net revenue
€568.00K - Gross margin
62.8% - EBIT
-€9.65M - EBIT margin
-1,699.1% - Net income
-€9.15M - Net margin
-1,610.9%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
No dividend payouts
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Bagai Shaun | Chief Executive Officer |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |